Bristol Myers Squibb Awards “Golden Tickets” to Promising Biotechs for Residencies at LabCentral, Biolabs@NYULangone and MBC BioLabs
Retrieved on:
Thursday, November 18, 2021
Health, Other Science, Clinical Trials, Pharmaceutical, Science, Biotechnology, This Year’s Winning Companies, Bristol Myers Squibb, LabCentral (Cambridge, MA), BioLabs@NYULangone (New York, NY), MBC BioLabs (San Francisco, CA), THIS YEAR’S WINNING COMPANIES, BRISTOL MYERS SQUIBB, LABCENTRAL (CAMBRIDGE, MA), BIOLABS@NYULANGONE (NEW YORK, NY), MBC BIOLABS (SAN FRANCISCO, CA)
Bristol Myers Squibb Company (NYSE:BMY) today announced five innovative biotech startups as winners of the companys 2021 Golden Ticket Contests.
Key Points:
- Bristol Myers Squibb Company (NYSE:BMY) today announced five innovative biotech startups as winners of the companys 2021 Golden Ticket Contests.
- For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .
- In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.
- MBC BioLabs has partnerships with leading pharmaceutical and life-science companies as well as a built-in venture capital firm, Mission BioCapital.